Optum Study Published in Reviews in Urology

Oncotype DX Genomic Prostate Score Test Results in Greater Adherence to Guideline-Based Care, According to Review of Nearly 10,000 Patient Records

According to real-world clinical evidence recently published in the Reviews in Urology, the use of the Oncotype DX Genomic Prostate Score test resulted in a more than 30 percent increase in the use of active surveillance at six and 12 months, compared to no GPS testing.

The study – the largest clinical utility study of a genomic test in prostate cancer patients to date – used the Optum™ Research Database of electronic health records and administrative claims. This included both commercial and Medicare Advantage health plans to assess active surveillance use for patients tested with the Oncotype DX GPS test.


Figure 2 from Canfield et al. Rev Urology. 2018.

“This publication solidifies the mounting evidence for the role of GPS testing in the initial management of early prostate cancer and its ability to appropriately drive active surveillance use among low-risk patients. No other test has this type of impact on driving guideline-based recommendations for these patients,” said Steven Canfield, M.D., chief of urology at UT Heath McGovern Medical School and lead author of the study.

The results were consistent with previous clinical utility studies1 demonstrating a substantial increase in the appropriate use of active surveillance with the GPS test in patients who otherwise may have received immediate treatment such as surgery and/or radiation.

1. Studies include Dall’Era et al. Urology Practice. 2015, Albala et al. Rev Urology. 2016, and Eure et al. Urology. 2017

Biology Matters: DOWNLOAD THE INFOGRAPHIC
Oncotype DX My Colon Cancer Coach